Sélectionner la langue
CEACAM-5
CEACAM-5 Informations sur la molécule
| Nom anglais | Carcinoembryonic antigen related cell adhesion molecule 5 | Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 18 | Alias de la cible | CEA Cell Adhesion Molecule 5，CEACAM5，Meconium antigen 100，CEA，Carcinoembryonic Antigen Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen，CD66e Antigen，CD66e |
| Phase de R&D la plus avancée | Phase 3 Clinical | ||
| Nom anglais | Carcinoembryonic antigen related cell adhesion molecule 5 |
| Alias de la cible | CEA Cell Adhesion Molecule 5，CEACAM5，Meconium antigen 100，CEA，Carcinoembryonic Antigen Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5，Carcinoembryonic Antigen，CD66e Antigen，CD66e |
| Nombre de médicaments commercialisés | 0 |
| Nombre de médicaments cliniques | 18 |
| Phase de R&D la plus avancée | Phase 3 Clinical |
CEACAM-5 Liste de produits
- Attribut
Protein (18)Cell (2)Cell Grade Beads (1)Beads (1)
- Bibliothèque de produits
En ligne (22)
- Espèces
Human (16)Mouse (2)Cynomolgus (3)Rhesus macaque (1)
- Étiquette
His Tag (8)His Tag & Avi Tag (4)Fc Tag (3)Fc Tag & Avi Tag (1)Llama IgG Fc Tag (2)- (4)
- Marqueur
Unconjugated (11)Biotin-labeled (5)FITC Labeled (2)- (4)
Ajouter au panier
Quantité totale22
- 1
- 2
- 3
CEACAM-5Contexte de la molécule
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) is also Carcinoembryonic antigen (CEA), Meconium antigen 100, CD antigen CD66e, CEACAM5 belongs to the immunoglobulin superfamily and CEA family. CEACAM5 contains seven Ig-like (immunoglobulin-like) domains. CEACAM5 is homodimer protein which binding of E.coli Dr adhesins leads to dissociation of the homodimer. CEACAM5 is cell surface glycoprotein that plays a role in cell adhesion and in intracellular signaling. CEACAM5 is receptor for E.coli Dr adhesins.
CEACAM-5Alias de la molécule
CEACAM-5,CD66e,CEA,Meconium antigen 100
Informations sur les médicaments cliniques
| Nom anglais | Code de recherche | Phase de R&D | Entreprise | Indication | Essai clinique |
|---|---|---|---|---|---|
| Tusamitamab Ravtansine | SAR-408701; IBI-126 | Phase 3 Clinical | Immunogen Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lung Neoplasms; Metastatic breast cancer; Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms | Details |
| SGM-101 | SGM-101 | Phase 3 Clinical | Surgimab Sas | Brain Diseases; Brain metastases; Brain Neoplasms; Colonic Diseases; Colonic Neoplasms; Colorectal Neoplasms; Gastrointestinal Diseases; Gastrointestinal Neoplasms; Intestinal Diseases; Intestinal Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms | Details |
| Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute) | CVAC-301; CV-301 | Phase 2 Clinical | Therion Biologics | Adenocarcinoma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma; Intestinal Neoplasms; Melanoma; Neoplasm Metastasis; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms | Details |
| NEO-201 | NEO-201 | Phase 2 Clinical | National Cancer Institute, Precision Biologics Inc | Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck; Uterine Cervical Neoplasms; Uterine Neoplasms | Details |
| Anti-CEA CAR T cell therapy (Shanghai GeneChem) | Phase 2 Clinical | Shanghai Genechem Co Ltd | Colorectal Neoplasms; Liver Neoplasms | Details | |
| BMS-986490 | BMS-986490 | Phase 2 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details |
| LM-24C5 | LM-24C5 | Phase 2 Clinical | LaNova Medicines Ltd | Neoplasms; Solid tumours | Details |
| Precemtabart tocentecan | M-9140; M9140 | Phase 2 Clinical | Merck KGaA, Darmstadt, Germany | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| MFE-23-CD3z T cell therapy (Cancer Research Technology) | Phase 1 Clinical | Cancer Research Technology | Neoplasms | Details | |
| anti-CEA CAR T-cell therapy (Shanghai First Song Therapeutics) | Phase 1 Clinical | Shanghai Simcere Pharmaceutical Co Ltd | Colorectal Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Small Intestine Cancers; Solid tumours; Stomach Neoplasms | Details | |
| 125-Iodine-labeled MFE-23 | Phase 1 Clinical | Cancer Research UK | Neoplasms | Details | |
| anti-CEA CAR-T cell therapy (Sorrento/TNK therapeutics/Roger Williams Medical Center) | Phase 1 Clinical | Beth Israel Deaconess Medical Center | Adenocarcinoma; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours | Details | |
| CEACAM5-TOPO1 ADC (Bristol-Myers Squibb Company) | Phase 1 Clinical | Bristol-Myers Squibb Company | Solid tumours | Details | |
| 124I-M5A | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | Colorectal Neoplasms | Details | |
| IBI-3020 | IBI3020; IBI-3020 | Phase 1 Clinical | Xinda Biomedical Technology (Hangzhou) Co Ltd | Neoplasm Metastasis; Solid tumours | Details |
| SGN-CEACAM5C | PF-08046050; SGN-CEACAM5C; SAR445953; SAR-445953 | Phase 1 Clinical | Sanofi, Seagen Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms | Details |
| EBC-129 | EBC129; EBC-129 | Phase 1 Clinical | Experimental Drug Development Centre | Solid tumours | Details |
| GB-5012 | GB-5012 | Clinical | Shanghai Genbase Biotechnology Co Ltd | Colonic Neoplasms | Details |
- Informations sur la molécule
- Liste de produits
- Informations sur les médicaments cliniques
Partager vers :